위염환자에서 글립타이드 정(Sulglycotide 200 mg)의 치료 효과 이중 눈가림, 무작위 배정, 비교약 대조, 다기관 임상시험

Abstract

Background/Aims: Sulglycotide is a non-systemic drug, used in the treatment of peptic ulcer and gastritis. The aim of this study was to assess the therapeutic effect and safety of Gliptide (sulglycotide 200 mg) in comparison with Mucosta (rebamipide 100 mg) for treatment of gastritis. Materials and Methods: Two hundred and three symptomatic patients with erosive gastritis at endoscopy were randomized to re- ceive sulglycotide or rebamipide for four weeks. Therapeutic effects of the drugs for gastritis were evaluated by follow up endoscopic scoring systems and clinical symptoms. We also sought possible adverse effects of the two drugs. Results: Gliptide (sulglycotide) and Mucosta (rebamipide) treatment in symptomatic gastritis resulted in endoscopic improvement rates of gastritis by 52.0%, 60.6% in intention-to-treat (ITT) analysis, 53.4%, 61.1% in per protocol (PP) analysis, which means therapeutic effects was not different between the two groups. The symptom improvement rates in the sulglycotide and rebamipide treated group were 57.3%, 57.5% in ITT analysis, 54.7%, 58.8% in PP analysis, which mean statistically no significant difference between the two groups. Endoscopic findings such as cure rates of erosion, edema, improvement rates of redness, hemorrhage were